Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Giappone
  4. Japan Exchange
  5. Sankyo Co., Ltd.
  6. Notizie
  7. Altre lingue
    6417   JP3326410002

SANKYO CO., LTD.

(6417)
  Rapporto
Tempo differito Japan Exchange  -  07:00:00 03/02/2023
5140.00 JPY   -0.96%
26/01Enhertu di AstraZeneca è stato approvato nell'UE per il tumore al seno.
AN
2022Sankyo Co. fornisce una previsione di guadagno consolidato per l'anno 2023
CI
2022Sankyo Co., Ltd. annuncia il dividendo per il secondo trimestre conclusosi il 30 settembre 2022, pagabile il 1° dicembre 2022; fornisce una guida al dividendo per l'anno fiscale che terminerà il 31 marzo 2023
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settoreAnalisi MarketScreener
Notizie in altre lingue su SANKYO CO., LTD.
30/01Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment
26/01AstraZeneca's Enhertu approved in EU for breast cancer form
20/01Sankyo's Largest Shareholder Trims Stake in Firm
2022TOP NEWS: AstraZeneca receives host of EU approvals or recommendations
2022IFPMA President and CEO of UCB, Jean-Christophe Tellier welcomes Sunao Manabe, Presiden..
2022Daiichi and AstraZeneca hail promising breast cancer treatment results
2022CORRECT: AstraZeneca cancer drug shows encouraging results in trial
2022AstraZeneca cancer drug shows encouraging results in phase 1 trial
2022TOP NEWS: AstraZeneca's Enhertu lowers death risk in breast cancer
2022TOP NEWS: AstraZeneca receives three recommendations for EU approval
2022Sankyo Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, ..
2022Sankyo Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2022, Pa..
2022Daiichi Sankyo upgrades full-year outlook on strength of Enhertu drug
2022Sankyo Co., Ltd. Revises Consolidated Earnings Guidance for Year Ending March 31, 2023
2022Japanese stocks pare early gains as Fast Retailing weighs
2022Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the Unit..
2022Sankyo Co., Ltd. Provides Dividend Guidance for Second Quarter and for Year Ended March..
2022Sankyo Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2023
2022Sankyo: Notice concerning Determination of Certain Details of the Issuance of Stock Compe..
2022Sankyo to Grant Stock Compensation-type Options
2022Sankyo: Notice concerning Issuance of Stock Compensation-type Stock Options (Subscription..
2022Sankyo Co., Ltd. Provides Dividend Guidance for Second Quarter and for Year Ended March..
2022Sankyo Co., Ltd. Announces Dividend for the Year Ended March 31, 2022, Payable on June ..
2022Sankyo Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2023
2022Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-8..
2022Sankyo Acquires Own Shares for Nearly $6 Million in April
2022Sankyo: Notice concerning Status and Completion of Repurchase of the Company's Own Shares
2022Tranche Update on Sankyo Co., Ltd.'s Equity Buyback Plan announced on November 8, 2021.
2022Sankyo Co., Ltd.'s Equity Buyback announced on November 8, 2021, has expired with 3,258..
2022Sankyo: Notice concerning Status of Repurchase of the Company's Own Shares
2022Tranche Update on Sankyo Co., Ltd.'s Equity Buyback Plan announced on November 8, 2021.
2022Sankyo: Notice concerning Status of Repurchase of the Company's Own Shares
2022Sankyo's Attributable Profit Skyrockets 313% in April-December 2021
2022Sankyo: Presentation on Business Results for the First Nine Months of FY 3/2022
2022Sankyo: Consolidated Financial Statements for the First Nine Months of FY2022
2022Sankyo Co., Ltd. Announces Management Changes, Effective April 1, 2022
2022Sankyo Co., Ltd. Revises Earnings Guidance for the Year Ending March 31, 2022
2022Sankyo Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2022
2022Sankyo Acquires Own Shares for $24 Million in January
2022Sankyo: Notice concerning Status of Repurchase of the Company's Own Shares
2022EN DIRECTO DESDE LOS MERCADOS: Iberdrola, BBVA, Apple, BAS..
2022Transportation and Logistics Systems, Inc. Announces Executive Changes
2022Tranche Update on Sankyo Co., Ltd.'s Equity Buyback Plan announced on November 8, 2021.
2021AstraZeneca's Partner Doses First Patient in Late-Stage Trial of Enhertu in Patients Wi..
2021Sankyo Eyes Prime Market Listing
2021Sankyo: Notice concerning Application for Selection of Prime Market in New Market Segment..
2021Sankyo Acquires Own Shares for $23 Million
2021Sankyo: Notice concerning Status of Repurchase of the Company's Own Shares
2021Presentation on Business Results for the First Six Months of FY 3/2022
2021Notice regarding Repurchase of Own Shares
2021Consolidated Financial Statements for the First Six Months of FY2022
2021Sankyo Co., Ltd. Provides Year End Dividend Forecast of for the Year Ending March 31, 2..
2021Sankyo Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2022
2021Sankyo Co., Ltd. announces an Equity Buyback for 3,500,000 shares, representing 5.71% f..
2021Sankyo Co., Ltd. authorizes a Buyback Plan.
2021Tranche Update on Kaga Electronics Co.,Ltd.'s Equity Buyback Plan announced on August 5..
2021Kaga Electronics Co.,Ltd.'s Equity Buyback announced on August 5, 2021, has expired wit..
2021Kaga Electronics Co.,Ltd. announces an Equity Buyback for 1,300,000 shares, representin..
2021Sankyo Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended Ju..
2021Sankyo Co., Ltd. Provides Dividend Forecast for the Second Quarter and Fourth Quarter o..
2021Sankyo Co., Ltd. Provides Earnings Forecast for the Year Ending March 31, 2022
2021Kaga Electronics Co.,Ltd. authorizes a Buyback Plan.
2021Sankyo: Notice concerning Determination of Certain Details of the Issuance of Stock Compe..
2021Sankyo: Notice concerning Issuance of Stock Compensation-type Stock Options (Subscription..
2021Sankyo: Notice concerning Personnel Changes
2021Sankyo: Presentation on Business Results of FY 3/2021
2021Sankyo: Consolidated Financial Statements Results for the fiscal year ended March 31, 202..
2021Sankyo: Notice concerning Redution of Directors' and Officers' Compensation
2021Sankyo Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2022
2021Sankyo Co., Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the F..
2021Sankyo Co., Ltd. Announces Dividend for the Year Ended March 31, 2021, Payable on June ..
2021Sankyo Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year 2022 ..
2021Sankyo: Notice concerning Change of Representative Directors
2021Sankyo: Notice concerning Organizational Changes and Presonnel Changes
2021Sankyo Co., Ltd. Announces the Retirement of Kimihisa Tsutsui as Representative Directo..
2021Sankyo Co., Ltd. Announces Organizational Changes and Presonnel Changes
2021Daiichi Sankyo : Says Started First Vaccinations In A Phase 1/2 Clinical ..
2021Japan stocks end flat as investors await Fed, BOJ verdicts
2021Daiichi Sankyo to Transfer the Marketing and Distribution Rights to AstraZeneca
2021Sankyo : to Dissolve Subsidiary International Card System
2021Sankyo: Notice concerning Dissolution and Liquidation of a Consolidated Subsidiary
2021Sankyo: Notice concerning Revision of the Forecast of the Financial Results for the Year ..
2021Sankyo: Notice concerning Organizational Changes and Personnel Changes
2021Sankyo Co., Ltd. Announces Organizational Changes
2021Sankyo Co., Ltd. Revises Earnings Guidance for the Year Ending March 31, 2021
2021Japan shares extend gains to close at 30-yr high on recovery hopes
2021Japan stocks continue to surge on vaccine-fuelled recovery hopes
2021Japan's Nikkei closes above 30,000 on earnings rebound, economy growth hopes
2021Japan's Nikkei closes above 30,000 on earnings rebound, economy growth hopes
2021Japan shares edge higher driven by Honda's upbeat earnings outlook
2021Sankyo : Attributable Profit Plunges 68% in April-December 2020
2021Sankyo Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended Decemb..
2021Sankyo Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2021
2021Sankyo Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2021
2021Astrazeneca : bekommt EU-Freigabe für neues Brustkrebsmedikament
2021Japan stocks start year in red as Tokyo braces for state of emergency
2021Japanese shares fall as PM Suga considers state of emergency for Tokyo
2020Japan shares end near three-decade high after Trump signs stimulus bill
2020Japan stocks end higher on gains in drugmakers, tech stocks
2020Nikkei rises as pharma stocks gain on hopes of existing vaccines working on new virus s..
Prossimo evento su SANKYO CO., LTD.